Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study.
about
Thrombotic microangiopathy with targeted cancer agentsThe role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpuraInvestigational drugs in thrombotic thrombocytopenic purpura.Targeting B cells in severe thrombotic thrombocytopenic purpura--a road to cure?Attending rounds: microangiopathic hemolytic anemia with renal insufficiencyThrombotic microangiopathy: current knowledge and outcomes with plasma exchange.A case series of atypical presentations of thrombotic thrombocytopenic purpura.Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura.Management and outcomes for patients with TTP: analysis of 100 cases at a single institution.How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndromeHow I treat refractory thrombotic thrombocytopenic purpura.A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab.Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review.Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases.Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases.Rituximab: current status as therapy for malignant and benign hematologic disorders.Successful treatment of chronic recurrent life-threatening bleeding due to an acquired factor V Inhibitor with rituximab and steroids.Thrombotic thrombocytopenic purpura
P2860
Q24635904-5E4E8EBF-C8BD-4B39-A617-3A25099AA541Q28080631-68C232D7-5547-4774-BDFA-2501C1A45019Q33395696-87C20289-DD23-4AA4-BF8F-2666A9BD07ECQ33398799-349BF9BC-8052-43CA-B7C6-8F6A4F52C133Q33398895-50044F62-D7E9-4FDD-90E5-0E2646E347E0Q33399520-6C15AAD0-1E63-49E8-89FD-3F11EE1E1856Q33400508-DF398110-E78A-4189-86A4-FF0A6BF5FD1DQ33400631-AA46D595-12F5-4AD4-AB31-884751207F5BQ33407187-887E0775-16D1-4917-BAEE-2FEF7B19B07EQ33412445-50391E29-269C-489E-B089-BF19F33A17F2Q33421268-06E96850-84EB-47D1-8EE1-AE3FB0071904Q33421822-13D955EA-3E91-4164-B8A8-350DEBBD949BQ33430254-FFBB5AC0-55ED-4E5A-9C1A-87EBA751223DQ33440605-21E99605-FD2D-4DFA-B687-AC83D18E60B8Q35672416-BDD7CBBC-1980-466F-BF19-8CE5FEA4277AQ36336555-2D49DCF5-1819-4CE3-9BFF-E769AA120C7BQ37984551-AD3DAF2E-0E18-4EA0-A906-4F98294DB290Q45884512-BF5F1177-C111-4317-B039-F64F32B2045EQ57379903-427F0A32-59DB-40EA-BD68-E7729911CF9E
P2860
Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Efficacy and safety of rituxim ...... f a Spanish multicenter study.
@ast
Efficacy and safety of rituxim ...... f a Spanish multicenter study.
@en
type
label
Efficacy and safety of rituxim ...... f a Spanish multicenter study.
@ast
Efficacy and safety of rituxim ...... f a Spanish multicenter study.
@en
prefLabel
Efficacy and safety of rituxim ...... f a Spanish multicenter study.
@ast
Efficacy and safety of rituxim ...... f a Spanish multicenter study.
@en
P2093
P921
P1476
Efficacy and safety of rituxim ...... f a Spanish multicenter study.
@en
P2093
Ana Sebrango
Antonio Vidaller
Concepción Zamora
Federico Moscardó
Francisco Peña
Grupo Español de Aféresis
Guillermo Debén
Julio Del Río-Garma
María J Gómez
Misericordia Pujol
P304
P356
10.1016/J.TRANSCI.2010.09.018
P577
2010-10-12T00:00:00Z